Hutchison China MediTech
Surufatinib granted FDA Orphan Drug Designation for Pancreatic NETHutchison China MediTech
NDA acceptance in China for surufatinib in non-pancreatic NETHutchison China MediTech
Publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancersHutchison China MediTech
Global collaboration with Innovent expanded to include surufatinibHutchison China MediTech
Initiation of international Phase I/Ib trial of HMPL-523 in advanced relapsed or refractory lymphomaHutchison China MediTech
CK Hutchison prices Chi-Med share offering enabling deconsolidation & confirms intent to hold Chi-Med as a long-term strategic investmentHutchison China MediTech
Chi-Med to discuss surufatinib Phase III and US Phase I/Ib efficacy and safety data presented at ESMOHutchison China MediTech
Presentation of clinical data from the successful Phase III SANET-ep trial at ESMO